Tarsier Pharma

Company Overview

Snapshot

Founded in January 2016 by Daphne Haim-Langford, Tarsier Pharma operates with 11–50 employees. The company has raised $5.65M across three funding rounds. In May 2026, the company was reported to be advancing towards an IPO in New York.

Business overview

Tarsier Pharma is a late-clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic approaches for autoimmune inflammatory ocular diseases. The company's core technology, the TRS Platform, is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular conditions. This platform is being developed as both eye drops and intravitreal injections, aiming to control a range of autoimmune and inflammatory ocular diseases as effectively as steroids but without the associated side effects. Tarsier Pharma operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the global pharmaceutical market.

Strategic signal

In May 2026, Tarsier Pharma was reported to be progressing towards an IPO in New York. This development signals strong investor confidence and a potential pathway for significant capital infusion, indicating a critical growth phase for the company as it seeks to commercialize its late-clinical-stage treatments for autoimmune inflammatory ocular diseases.

Company Intelligence Q&A

What is Tarsier Pharma's primary focus?

Tarsier Pharma is a late-clinical-stage company dedicated to developing and commercializing breakthrough therapeutic approaches for autoimmune inflammatory ocular diseases.

When did Tarsier Pharma complete patient enrollment for its TRS01 clinical trial?

Tarsier Pharma completed patient enrollment in the clinical trial of TRS01 for patients with non-infectious uveitis in June 2020.

What significant regulatory milestone did Tarsier Pharma achieve for TRS in Europe?

In November 2019, Tarsier Pharma announced the granting of Orphan Drug Designation for TRS by the European Medicines Agency.

What was the outcome of Tarsier Pharma's End-of-Phase 2 meeting with the U.S. FDA?

In December 2020, Tarsier Pharma had a positive End-of-Phase 2 meeting with the U.S. FDA, setting the stage for the TRS01 Phase III program in uveitis.

What new product development did Tarsier Pharma announce in August 2022?

In August 2022, Tarsier Pharma announced the development of TRS02, a potential immunomodulator for the treatment of retinal diseases with a sustained-release intravitreal formulation.